Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China
20 Mar, 2015, 10:30 GMT
MUMBAI, March 20, 2015 /PRNewswire/ --
This is first time in history, Chinese pharmaceutical authorities officially issued a guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. The guidance provides an opportunity to reduce risk from the examination uncertainty and approval delays to eat up your time and energy to achieve a successful entry into such a lucrative drug market, and to avoid trouble for your business smoothly in China. The overseas and multinational pharmaceutical manufacturers must be compliance with the latest regulations.
Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China provided a comprehensive and thorough knowledge of the Guidance on international multi-center clinical trials of drugs in China and guide you use the Chinese trial venues to keep drug development lean and to smoothly operate in China.
China's healthcare market is indispensable for overseas and multinational pharmaceutical companies, but Chinese regulations on pharmaceutical clinical trials are undergoing sharp changes. This is first time in history, Chinese pharmaceutical authorities officially issued guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. To enter into Chinese lucrative drug market, the overseas and multinational pharmaceutical manufacturers must be compliance with this latest regulations. How do respond such challenges? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the Guidance on Chinese international multi-center clinical trials of drugs, and must be compliance with the latest regulations.
To order this report and request for sample page:
The organizations of this guidebook are arranged as follows.
- Chapter 2 provides an overview of the Chinese regulatory authorities -- China Food and Drug Administration (CFDA) being responsible for application and approval for international multi-center clinical trials of drug registration to give the direction of gateway for application for approval of clinical trial of imported overseas drug registration.
- Chapter 3 elaborates the background of promulgating Guidance.
- Chapter 4 introduces the applicable scope of Guidance.
- Chapter 5 introduces the general requirements of international multi-center clinical trials of drugs in China.
- Chapter 6 elaborates a series of scientific issues that Guidance requires sponsors to be considered.
- Chapter 7 elaborates a series of compliance issues that Guidance requires sponsors to be considered.
- Chapter 8 elaborates the clinical trial protocol amendment.
- Chapter 9 introduces the requirements for using the data from international multi-center clinical trials to support the application for drug registration in China.
- Chapter 10 introduces the authority, objects, contents, scope and requirements of Chinese drug regulatory authorities implementing inspection and verification on clinical trial sites.
- Chapter 11 provides a comprehensively and thoroughly practical guidance for application and approval of pharmaceutical international multi-center clinical trials in China, from the knowledge preparation and operation preparation before application, the specific regulations on overseas applicant and application, to the practical operation of application for approval as well as registration and information disclosure of international multi-center clinical trials of drugs in China to smoothly navigate complex regulatory requirements step by step.
- Chapter 12 provides a comprehensively comparative analysis to reveal the opportunities and challenges of international multi-center clinical trials of drugs in China, and to tell overseas and multinational pharmaceutical companies how to respond challenges.
- Chapter 13 Appendices provide a complete set of full text in English of application forms involved in application for approval of pharmaceutical international multi-center clinical trials in China, which include "Application Form of Drug Registration", "Application Form for Special Examination and Approval of New Drug Registration", and "Application Form for Communication of Special Examination and Approval of New Drug Registration".
Report Highlights
- An overview of organizational structure of Chinese regulatory authorities -- China Food and Drug Administration (CFDA) for approval for international multi-center clinical trials in China to give the direction of gateway for clinical trials of imported drugs.
- The background of promulgating Guidance.
- The applicable scope of Guidance.
- The general requirements of international multi-center clinical trials of drugs in China.
- A series of scientific issues that overseas sponsors must be considered.
- A series of compliance issues that overseas sponsors must be considered.
- The detailed requirements for using the data from international multi-center clinical trials to support the application for imported overseas drug registration in China.
- Chinese drug regulatory authorities how to implement the inspection and verification on clinical trial sites.
- A comprehensively and thoroughly practical guidance for application and approval of pharmaceutical international multi-center clinical trials in China, from the knowledge preparation and operation preparation before application, the specific regulations on overseas applicant and application, to the practical operation of application for approval as well as registration and information disclosure of international multi-center clinical trials of drugs in China to smoothly navigate complex regulatory requirements step by step.
- An entire process of application and approval procedures for international multi-center clinical trials of drugs in China.
- The detailed regulations on registration and information disclosure for international multi-center clinical trials of drugs in China.
- A comprehensively comparative analysis to reveal the opportunities and challenges of international multi-center clinical trials of drugs in China, and to tell overseas and multinational pharmaceutical companies how to respond challenges.
- A complete set of full text in English of application forms involved in application for approval of pharmaceutical international multi-center clinical trials in China, which include "Application Form of Drug Registration", "Application Form for Special Examination and Approval of New Drug Registration", and "Application Form for Communication of Special Examination and Approval of New Drug Registration".
Content
1. Chapter 1 Executive Summary
2. Chapter 2 An Overview of Chinese Regulatory Authorities for Drug Clinical Trials
- CFDA's Main Responsibilities
- CFDA's Organizational Structure
- Roadmap of Application and Approval for Clinical Trials of Imported Drug Registration
3. Chapter 3 Background
4. Chapter 4 Applicable Scope
5. Chapter 5 General Requirements
- Basic Conditions of International Multi-center Clinical Trials for Drugs
- Selection of Strategies for International Multi-center Clinical Trials of Drugs
- Requirements for Accepting International Multi-center Clinical Trial Data for Drug Registration in China
6. Chapter 6 Consideration for Scientific Issues
- Epidemiology of Disease
- Differences in Medical Practice
- Differences in Drug Metabolism
- Selection of Dose
- Selection of Control Drugs
- Assessment Indexes of Efficacy
- Consideration for Sample Size
- Consideration for Statistics
- Collection and Assessment of Adverse Events / Reactions
- Other Consideration Issues
7. Chapter 7 Consideration for Compliance Issues
- Application for Approval of Clinical Trials and Information Publicity
- Approval of Ethics Committee
- Language of Documents
- Informed Consent
- Information Submission
- Compensation to Trial Subjects
- Information about Clinical Trial Drug
- Biological Samples
- Data Processing Centers
- Collection and Assessment of Adverse Events (AE)
- Application of Computerized System
- Monitoring and Verifying for Clinical Trial Centers
8. Chapter 8 Clinical Trial Protocol Amendment
9. Chapter 9 Application for Drug Registration
10. Chapter 10 Inspection and Verification on Sites
11. Chapter 11 Practical Guidance for Application and Approval of Pharmaceutical International Multi-Center Clinical Trials in China
- Knowledge Preparation before Application for Approval of International Multi-Center Clinical Trials of Drugs in China
- Specific Regulations on Overseas Applicant to Apply for International Multi-Center Clinical Trials of Drugs in China
- Special Examination and Approval Procedures for Innovative Drugs, New Drugs for Treatment of Difficult and Critical Diseases
- What Pharmaceutical Products may be Applied for International Multi-Center Clinical Trials in China
- Practical Guidance for Application and Approval of Pharmaceutical International Multi-Center Clinical Trials in China
- Preparation before Application for Approval of International Multi-Center Clinical Trials of Drugs in China
- Specific Provisions on Application for Approval of International Multi-Center Clinical Trials of Drugs in China
- Practical Operation of Application for Approval of International Multi-Center Clinical Trials of Drugs in China
- Application and Approval Procedure for International Multi-Center Clinical Trials of Drugs in China
- Registration and Information Disclosure for International Multi-Center Clinical Trials of Drugs in China
12. Chapter 12 A Comprehensive Analysis Opportunities and Challenges of International Multi-Center Clinical Trials of Drugs in China.
- What are Opportunities of International Multi-Center Clinical Trials in China?
- What are Challenges of International Multi-Center Clinical Trials in China?
13. Appendices
- Application Form for Special Examination and Approval of New Drug Registration
- Application Form for Communication of Special Examination and Approval of New Drug Registration
- Application Form of Drug Registration
Related Reports
- Glomerulonephritis Global Clinical Trials Review, H1, 2015
About Bharat Book Bureau
Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.
Blog: https://www.bharatbook.com/blog/
Website: https://www.bharatbook.com/
Contact Details:
Poonam
Bharat Book Bureau
India: +91-22-27810772, 27810773
E-mail: poonam@bharatbook.com
SOURCE Bharat Book Bureau